Exosome RNA Exosome RNA Research & Industry News
SAN DIEGO, Nov. 6, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that officials at Frankfurt University Hospital have reported undetectable virus in an ebola patient previously disclosed to have received Hemopurifier® therapy. In an article entitled: “Ugandan Doctor Cured of Ebola in Germany,” The Wall Street Journal has reported that hospital officials indicated the patient is no longer infected with ebola virus and is heading toward a full recovery.
The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. According to the World Health Organization (WHO), more than 5,000 deaths have been attributed to the current ebola virus epidemic. The patient at Frankfurt University Hospital was administered Hemopurifier® therapy through special approval from The Federal Institute for Drugs and Medical Devices (Bundesinstitut fur Arzneimittel und Medizinprodukte, BfArM), an independent federal higher authority within the portfolio of the Federal Ministry of Health of Germany.
“It is truly wonderful that the patient, who was reported to be suffering from multiple organ failure, is now recovering from ebola infection,” stated Aethlon founder and CEO, Jim Joyce. “In the coming days, we will disclose the venue of a public presentation that will report treatment data including the quantification of viral load reduction and viruses captured by our Hemopurifier during the treatment of this patient.”
In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating viruses to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response. The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.
Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration’s (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).
To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).
About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/
Source – PR Newswire
